Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Brain Neoplasms × tucatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Colorectal Neoplasms 3 Stomach Neoplasms 2 Adenocarcinoma Of Esophagus 2 Meningeal Neoplasms 1 HER2-positive Breast Cancer 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Temozolomide 50 Bevacizumab 42 Radiotherapy 28 Radiosurgery 18 Carboplatin 14 Erlotinib Hydrochloride 10 Radiation 9 pembrolizumab 8 Vorinostat 8 Magnetic Resonance Spectroscopy 8 Irinotecan 8 Trastuzumab 7 Radiotherapy, Intensity-Modulated 7 Etoposide 7 Capecitabine 7 Lomustine 6 Lapatinib 6 dabrafenib 5 Sunitinib 5 Sorafenib 5 Ipilimumab 5 Imatinib Mesylate 5 Everolimus 5 Cyclophosphamide 5 cabozantinib 4 binimetinib 4 Therapeutics 4 Radiotherapy, Conformal 4 NVP-BKM120 4 Immunoglobulin G 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02614794 2023-08-14

HER2CLIMB

Seagen Inc.

Phase 2 Completed

612 enrolled 30 charts 2 FDA

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡